Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.
Max A A RagusiB H M van der VeldenM C van MaarenE van der WallC H van GilsR M PijnappelK G A GilhuijsS G EliasPublished in: Breast cancer research and treatment (2022)
Based on PREDICT, AST prevents 10-year breast cancer death in 6.4% of the patients treated with AST. Consequently, AST yields no survival benefit to many treated patients. Especially improved personalization of endocrine therapy is relevant, as this therapy is widely used and is associated with the highest amount of overtreatment.